Press Releases Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 20/06/2025 BST			5-day change	1st Jan Change
1,377.00 ^DKK	-1.78%		-7.02%	-7.74%

06-17	Genmab A/S, Q1 2025 Earnings Call, May 08, 2025
06-16	Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	MT

Press Releases

Genmab A/S : Articles of association dated June 12, 2025 – English	06-18	PU
Genmab A/S : Articles of association dated June 17, 2025 – English	06-18	PU
Genmab A/S : has published its Articles of Association	06-18	PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise	06-17	GL
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	06-17	GL
Genmab A/S - Transactions in Connection with Share Buy-back Program	06-17	AQ
Genmab A/S : has published its Articles of Association	06-16	PU
Transactions in Connection with Share Buy-back Program	06-16	GL
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	AQ
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	GL
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)	06-15	BU
Grant of Restricted Stock Units and Warrants to Employees in Genmab	06-12	GL
Transactions in Connection with Share Buy-back Program	06-10	GL
Genmab A/S : Rina-S Update at ASCO 2025	06-02	PU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	06-02	BU
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial	06-02	GL
Transactions in Connection with Share Buy-back Program	06-02	GL
Genmab A/S - Transactions in Connection with Share Buy-back Program	05-27	AQ
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	05-27	GL
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference	05-27	AQ
Transactions in Connection with Share Buy-back Program	05-26	GL
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	05-22	BU
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	05-22	GL
Genmab A/S : Articles of association dated May 20, 2025 – English	05-21	PU
Genmab A/S : has published its Articles of Association	05-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : Beaten up share price offers an opportunity

June 06, 2025 at 01:40 pm

Genmab: From now on, courage to the most patient

April 01, 2025 at 03:57 pm